Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 831 results for "gilead sciences"

Gilead Sciences (NASDAQ:GILD) Rating was Downgraded by Analysts at Maxim Group to a Hold Rating

Gilead Sciences (NASDAQ:GILD) Rating was Downgraded by Analyst...

Gilead Sciences (NASDAQ:GILD) Downgrade Maxim Group cut Gilead Sciences (NASDAQ:GILD)'s stock to Hold rating from Buy. This rating change was sent to clients and investors in an analyst report today. The rating downgrade is noticed by stock ... Octafinance, 3 hours ago
Gilead Sciences is Oversold ACQ Magazine, 4 hours ago

Merck's pockets to remain empty as judge reopens sofosbuvir patent case with Gilead; $200M award most likely years away

A misstep by a Merck scientist prompts the judge to reopen the patent dispute between Merck ( MRK +0.1%) and Gilead Sciences ( GILD -0.4%). During the first trial, in which Merck was awarded $200M, the jury found that Gilead infringed on two Merck ...
 Seeking Alpha4 hours ago Judge Allows More Evidence in Gilead-Merck Patent Dispute  4 Traders1 hour ago Judge Allows More Evidence in Patent Dispute After Gilead Says Merck Attorney Lied  4 Traders1 hour ago Gilead Reports Drop in Hepatitis C Drug Revenue  4 Traders4 days ago
Motley Fool

Good News: Gilead Sciences Discounted Its Drugs Again

Why lower revenue per patient is a good thing (or at least necessary) Gilead Executive VP Paul Carter explained on the earnings call that sales fell in part because "several of the large commercial payers opened up access to patients regardless of ...
 Motley Fool4 hours ago

Don't Give Up on Gilead Following a Weak Q1

Keep an eye on Gilead Sciences ( (GILD - Get Report) ), whose shares are likely to reverse some of their recent losses amid news that its patent lawsuit with Merck ( (MRK - Get Report) ) over a hepatitis C drug will be re-opened. The case is back ...
 TheStreet.com6 hours ago

Gilead Sciences is Oversold

You must learn from other people's mistakes. You can't possibly live long enough to make them
 Forbes.com6 hours ago

Merck making inroads in HCV market with aggressive pricing of Zepatier

According to comments from competitors AbbVie ( ABBV +0.6%) and Gilead Sciences ( GILD -0.4%), Merck ( MRK +0.2%) is grabbing share in the hepatitis C virus (HCV) market with aggressive pricing of combo treatment Zepatier (elbasvir and grazoprevir), ...
 Seeking Alpha6 hours ago

Federal Judge Reopens Gilead Case Amid Allegations Former Merck & Co. Scientist Lied

A federal judge re-opened Merck & Co.'s patent case against Gilead Sciences Inc. over a hepatitis C drug amid claims that an ex-Merck scientist lied to a jury that awarded the company $200 million in damages. U.S. District Judge Beth Labson Freeman ...
 BioSpace8 hours ago Gilead Judge Re-Opens Case Amid Claim Merck Scientist Lied  Bloomberg2 days ago Federal Judge Reopens Gilead Case Versus Merck & Co.  Pharma Live2 hours ago

Gilead shares fall after company misses on revenue

The business's quarterly revenue was up 2.6% compared to the same quarter previous year. In other Gilead Sciences news, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, February 1st. For its ...
 Equilibrio Informativo19 hours ago
Bidness Etc

Gilead Sciences, Inc Earnings Miss: What Went Wrong?

For the first time in a long while, Gilead Sciences, Inc. ( NASDAQ:GILD ) ended up disappointing investors with its earnings data. The biotech giant missed on sales estimates for the first quarter of 2016, as its mainstay hepatitis C franchise saw a ...
 Bidness Etc3 days ago Amazon, LinkedIn, Gilead, & More: Here's Why These Stocks Are Trending Today  InsiderMonkey.com3 days ago U.S. Index Futures Little Changed as Amazon Jumps, Gilead Falls  La Repubblica3 days ago US STOCKS-Healthcare stocks, weak data weigh on Wall St  Sify3 days ago

Gilead's Profit, Hepatitis C Drugs Sales Miss Estimates

Gilead Sciences Inc.'s profit missed analysts estimates in the first quarter as sales of its blockbuster hepatitis C treatments were less than expected. Profit excluding some costs totaled $3.03 per share, falling short of the $3.15 average ...
 Bloomberg4 days ago Forced to discount pricey hepatitis C drugs, Gilead misses sales target  StatNews.com3 days ago Gilead's Q1 results dampened by slower hepatitis C drug sales  FirstWord Pharma4 days ago Gilead 1st qtr hepatitis C drug sales, profit fall short  Sharenet4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
Get updated on latest news & your favorite topics right in your inbox!
More     Less